Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10226292 | 0.98 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL10226299 | 0.98 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL1274108 | 0.98 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL5460363 | 0.98 | CA14 (0.53) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL31324971 | 0.96 | CA14 (0.51) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL7207297 | 0.94 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL7947788 | 0.94 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL7202844 | 0.94 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL7797763 | 0.93 | CA14 (0.50) | CA14HDAC6HDAC1HDAC2ACHE | |
| SCHEMBL12665089 | 0.93 | CA14 (0.50) | CA14HDAC6HDAC1HDAC2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| WO-2024167198-A1 | POLYAMINE-CONJUGATED ASCORBIC ACID DERIVATIVE AND MANUFACTURING METHOD THEREFOR | 주식회사 카파바이오사이언스 | 2024-08-15 | — | — | WO | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2011019839-A2 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| US-7411002-B2 | Polycationic sulfonamides and use thereof | THE UNIVERSITY OF KANSAS (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1893232-A2 | NEW ADJUVANT | GLAXO GROUP LIMITED (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070287750-A1 | Polycationic sulfonamides and use thereof | THE UNIVERSITY OF KANSAS (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2006136460-A2 | NEW ADJUVANT | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | CA14 2154/4885HDAC6 4110/4885HDAC1 4389/4885 |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | CA14 3505/4885HDAC6 4009/4885HDAC1 4175/4885 |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | RXFP2, RXFP1, RXFP4 | CA14 3656/4885HDAC6 3983/4885HDAC1 4013/4885 |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | CA14 3505/4885HDAC6 4009/4885HDAC1 4175/4885 |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | CA14 3935/4885HDAC6 3922/4885HDAC1 3845/4885 |
| US-20070287750-A1 | Polycationic sulfonamides and use thereof | STS, PTDSS2, PTDSS1 | CA14 671/4885HDAC6 1304/4885HDAC1 935/4885 |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | CA14 2685/4885HDAC6 1169/4885HDAC1 1034/4885 |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | CA14 2685/4885HDAC6 1169/4885HDAC1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.